EGFR and neoplasm: Truncated mutant EGFR variant III expression, in which exons 2–7 are deleted, was detected in 42% of HNSCC tumors, resulting in constitutive activation of EGFR, increased proliferation and tumor volume, and enhanced resistance to targeting wild-type EGFR [65].